Carsten Schou

Director/Board Member at Minervax ApS

Health Technology

Finance

Consumer Services

Profile

Carsten Schou is currently the Director at Minervax ApS and the General Partner at SEED Capital Management I.
He previously held positions as Research Director at ALK-Abello A, Director-Biotechnology Research & Innovation at the University of Copenhagen, Director at Celltrix AB, Valderm ApS, Neurokey A, Bok Holding A, OncoTac Pharmaceuticals ApS, EpiTherapeutics ApS, Non-Executive Director at CanImGuide Therapeutics AB, Director at Reapplix A, Acarix AB, Contera Pharma ApS, MedicoSelskabet September 2014 ApS, Acesion Pharma ApS, Galecto Biotech ApS, Evolva A, and Principal at Danske Private Equity A.
He received a graduate degree from the University of Copenhagen and a doctorate degree from Statens Serum Institute.

Carsten Schou active positions

Companies	Position	Start
SEED Capital Management I/S SEED Capital Management I/S Investment ManagersFinance SEED Capital Management I/S is an Independent Venture Capital firm founded in 2004. The company is headquartered in Copenhagen, Denmark.	Private Equity Investor	2004-11-30
Minervax ApS Minervax ApS Medical SpecialtiesHealth Technology Minervax ApS provides vaccine against streptococci. It utilizes fusion protein, which has proved to elicit good protective immunity. Its vaccine provides protective immunity against many clinically relevant GBS strains. The firm is engages in biotechnology, scientific and technical activities, and research and development. The company was founded in 2010 and is headquartered in Copenhagen, Denmark.	Director/Board Member	-

All active positions of Carsten Schou

Former positions of Carsten Schou

Companies	Position	End
Valderm ApS Valderm ApS Pharmaceuticals: MajorHealth Technology Valderm ApS is focused on the development of the second generation anthracycline valrubicin for innovative once daily topical treatment of hyper proliferative skin diseases e.g. psoriasis. Preclinical studies have confirmed the anti-proliferative effect of valrubicin and an attractive safety profile upon repeated topical applications has been documented. The company was founded in 2003 and is headquartered in Lyngby, Denmark.	Director/Board Member	2014-05-20
OncoTac Pharmaceuticals ApS OncoTac Pharmaceuticals ApS Pharmaceuticals: MajorHealth Technology OncoTac Pharmaceuticals ApS develops and commercializes therapeutics for the treatment of cancer diseases. The company was founded by Thomas Senderovitz, John Rømer Nielsen, Charles Pyke, Paul Kristjansen, and Søren Pontoppidan and is headquartered in Copenhagen, Denmark.	Director/Board Member	2012-04-01
Neurokey A/S Neurokey A/S Pharmaceuticals: MajorHealth Technology Neurokey wants to become a leading drug development company in the critical care field. The drugs under development will one day help countless patients suffering from the effects of debilitating and potentially fatal cardiovascular and neurological; diseases. Neurokey will be first to market with reliable efficient and easily administered medication that will increase the survival rate for these patients and dramatically minimize the risk of permanent neurological damage.	Director/Board Member	2010-07-29
Acesion Pharma ApS Acesion Pharma ApS Pharmaceuticals: MajorHealth Technology Acesion Pharma ApS develops drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia. The firm's technology blocks ion channel with a selective drug molecule constitutes a target for developing treatment of AF. The company was founded by Ulrik Svane S?rensen and Morten Grunnet in 2011 and is headquartered in Copenhagen, Denmark.	Director/Board Member	-
University of Copenhagen	Corporate Officer/Principal	-

See the detail of Carsten Schou's experience

Training of Carsten Schou

University of Copenhagen	Graduate Degree
Statens Serum Institute	Doctorate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Carsten Schou's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	2
ACARIX AB	Health Technology
ALK-ABELLÓ A/S	Health Technology

Private companies	16
SEED Capital Management I/S SEED Capital Management I/S Investment ManagersFinance SEED Capital Management I/S is an Independent Venture Capital firm founded in 2004. The company is headquartered in Copenhagen, Denmark.	Finance
Valderm ApS Valderm ApS Pharmaceuticals: MajorHealth Technology Valderm ApS is focused on the development of the second generation anthracycline valrubicin for innovative once daily topical treatment of hyper proliferative skin diseases e.g. psoriasis. Preclinical studies have confirmed the anti-proliferative effect of valrubicin and an attractive safety profile upon repeated topical applications has been documented. The company was founded in 2003 and is headquartered in Lyngby, Denmark.	Health Technology
Bok Holding A/S Bok Holding A/S BiotechnologyHealth Technology Bok Holding A/S is a holding company that operates as a biotechnology company that researches and develops cancer treatment solutions. It develops the ZAS platform technology which efficiently enhances the effect of current anti-cancer drugs and reduces toxicity. The firm employs molecular techniques commonly known as molecular breeding or directed enzyme evolution which can activate anti-cancer drugs. The company was founded by Zoran Gojkovic on November 22, 2001 and is headquartered in Gentofte, Denmark.	Health Technology
OncoTac Pharmaceuticals ApS OncoTac Pharmaceuticals ApS Pharmaceuticals: MajorHealth Technology OncoTac Pharmaceuticals ApS develops and commercializes therapeutics for the treatment of cancer diseases. The company was founded by Thomas Senderovitz, John Rømer Nielsen, Charles Pyke, Paul Kristjansen, and Søren Pontoppidan and is headquartered in Copenhagen, Denmark.	Health Technology
Neurokey A/S Neurokey A/S Pharmaceuticals: MajorHealth Technology Neurokey wants to become a leading drug development company in the critical care field. The drugs under development will one day help countless patients suffering from the effects of debilitating and potentially fatal cardiovascular and neurological; diseases. Neurokey will be first to market with reliable efficient and easily administered medication that will increase the survival rate for these patients and dramatically minimize the risk of permanent neurological damage.	Health Technology
EpiTherapeutics ApS EpiTherapeutics ApS BiotechnologyHealth Technology EpiTherapeutics ApS is a holding company that develops cancer drugs based on research in the field of epigenetics. Its development programs are focused on enzymes involved in the regulation of transcription in cancer - current programs target histone demethylases and methyltransferases. The firm's regulation is commonly used for post-translational covalent modifications of histones and other chromatin-remodeling complexes, which determines whether a gene is accessible and hence, expressed or repressed. Its covalent modifications involved in epigenetic regulation include deoxyribonucleic acid methylation, histone acetylation, and histone methylation. The company was founded by Kristian Helin, Paul Andreas Compare Cloos, Jesper Aagaard Christensen, Karl Agger, and Klaus Hansen on September 18, 2008 and is headquartered in Greve, Denmark.	Health Technology
Reapplix A/S Reapplix A/S Medical DistributorsDistribution Services Reapplix A/S specializes in the biological treatment and management of diabetic foot ulcers. It develops the LeucoPatch device, which is composed of precision molded medical grade plastic components, that facilitates a processing of autologous blood. The company was founded by Niels Erik Holm and Rasmus Lundquist in 2008 and is headquartered in Birkerod, Denmark.	Distribution Services
Galecto Biotech ApS Galecto Biotech ApS Pharmaceuticals: MajorHealth Technology Galecto Biotech ApS provides galectin modulators for the treatment of severe diseases, including fibrosis and cancer. Its products include galectin-3 inhibitors, fibrosis and literature. The company was founded by Tariq Sethi, Hans Thalsgard Schambye, Ulf Jorgen Nilsson, and Hakon Leffler in 2011 and is headquartered in Copenhagen, Denmark.	Health Technology
Contera Pharma ApS Contera Pharma ApS Pharmaceuticals: MajorHealth Technology Contera Pharma ApS is a holding company that identifies and develops treatments for patients suffering from movement disorders. It develops drug candidates based on a combination of repositioning, combinations, and reformulations. The firm's lead project JM-010 is for treatment of dyskinesia associated with Parkinson's disease. It develops an approach of using a combination therapy to tackle clinically relevant synergistic pathways to obtain therapeutic effects which will generate efficacious therapeutic entities based on robust pre-clinical and clinical evidence. The company was founded by Mikael Søndergaard Thomsen and John Bondo Hansen in 2010 and is headquartered in Copenhagen, Denmark.	Health Technology
Celltrix AB Celltrix AB Medical SpecialtiesHealth Technology Celltrix AB manufactures medical devices. It develops novel and injectable dermal filler for reconstructive cosmetic surgery, based on microbeads of cross-linked gelatine. The company was founded in December 2003 by Kjell Gösta Conny Nilsson and is headquartered in Malmö, Sweden.	Health Technology
MedicoSelskabet September 2014 ApS MedicoSelskabet September 2014 ApS Medical SpecialtiesHealth Technology MedicoSelskabet September 2014 ApS is a holding company that develops medical devices for cardiovascular sensing. Its scheme is based on a concept that does not interfere with the state of the patient. It improves the method of measuring hypertension and suitable for ambulatory continuous measurements. Its also involves in the repair of communication equipment. The company was founded by Ole Kjerulf Jensen and Lars Lading on June 14, 2002 and is headquartered in Hellerup, Denmark.	Health Technology
Danske Private Equity A/S Danske Private Equity A/S Investment ManagersFinance Danske Private Equity A/S (DPE) is a private equity fund of funds investment firm founded in 1999. The firm is headquartered in Lyngby.	Finance
Minervax ApS Minervax ApS Medical SpecialtiesHealth Technology Minervax ApS provides vaccine against streptococci. It utilizes fusion protein, which has proved to elicit good protective immunity. Its vaccine provides protective immunity against many clinically relevant GBS strains. The firm is engages in biotechnology, scientific and technical activities, and research and development. The company was founded in 2010 and is headquartered in Copenhagen, Denmark.	Health Technology
Acesion Pharma ApS Acesion Pharma ApS Pharmaceuticals: MajorHealth Technology Acesion Pharma ApS develops drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia. The firm's technology blocks ion channel with a selective drug molecule constitutes a target for developing treatment of AF. The company was founded by Ulrik Svane S?rensen and Morten Grunnet in 2011 and is headquartered in Copenhagen, Denmark.	Health Technology
Evolva A/S
CanImGuide Therapeutics AB CanImGuide Therapeutics AB Pharmaceuticals: MajorHealth Technology CanImGuide Therapeutics AB develops cancer therapies. The firm is a biotechnological company that reverses cancer related immunosuppression. It manufactures the proprietary drug P28R, a peptide with two modes of actions. The company was founded on March 21, 2006 and is headquartered in Hollviken, Sweden.	Health Technology